Upsher-Smith Laboratories LLC, a US subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472) (OTCQX:BORAY), announced on Thursday the launch of Glatiramer Acetate Injection in 20 mg/mL and 40 mg/mL strengths, adding to the company's portfolio of complex generic medicines.
According to IQVIA, the Glatiramer Acetate Injection market had US sales of approximately USD562m in the 12 months from June 2025 to May 2026.
The Therapeutic Equivalence (TE) code for Upsher-Smith's Glatiramer Acetate Injection product is AP, and the Reference Listed Drug (RLD) is the brand COPAXONE (glatiramer acetate injection) from Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA).
The drug is used to treat relapsing forms of multiple sclerosis (MS) in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease).
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Dexcel Pharma's Nintedanib Capsules approved for US launch
Upsher-Smith launches generic version of Ciprodex ear drop suspension